These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 9815763

  • 21. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against BCL-1 murine B-cell leukemia.
    Uckun FM, Chelstrom LM, Irvin JD, Finnegan D, Gunther R, Young J, Kuebelbeck V, Myers DE, Houston LL.
    Blood; 1992 May 15; 79(10):2649-61. PubMed ID: 1375109
    [Abstract] [Full Text] [Related]

  • 22. An immunotoxin composed of a monoclonal antitransferrin receptor antibody linked by a disulfide bond to the ribosome-inactivating protein gelonin: potent in vitro and in vivo effects against human tumors.
    Scott CF, Goldmacher VS, Lambert JM, Jackson JV, McIntyre GD.
    J Natl Cancer Inst; 1987 Nov 15; 79(5):1163-72. PubMed ID: 3500356
    [Abstract] [Full Text] [Related]

  • 23. Anti-T cell immunotoxins containing pokeweed anti-viral protein: potential purging agents for human autologous bone marrow transplantation.
    Ramakrishnan S, Uckun FM, Houston LL.
    J Immunol; 1985 Nov 15; 135(5):3616-22. PubMed ID: 3900212
    [Abstract] [Full Text] [Related]

  • 24. Treatment of human B-cell precursor leukemia in SCID mice by using a combination of the anti-CD19 immunotoxin B43-PAP with the standard chemotherapeutic drugs vincristine, methylprednisolone, and L-asparaginase.
    Ek O, Gaynon P, Zeren T, Chelstrom LM, Myers DE, Uckun FM.
    Leuk Lymphoma; 1998 Sep 15; 31(1-2):143-9. PubMed ID: 9720724
    [Abstract] [Full Text] [Related]

  • 25. Establishment of a human t(4;11) leukemia in severe combined immunodeficient mice and successful treatment using anti-CD19 (B43)-pokeweed antiviral protein immunotoxin.
    Jansen B, Uckun FM, Jaszcz WB, Kersey JH.
    Cancer Res; 1992 Jan 15; 52(2):406-12. PubMed ID: 1370213
    [Abstract] [Full Text] [Related]

  • 26. Favorable pharmacodynamic features and superior anti-leukemic activity of B43 (anti-CD19) immunotoxins containing two pokeweed antiviral protein molecules covalently linked to each monoclonal antibody molecule.
    Myers DE, Yanishevski Y, Masson E, Irvin JD, Evans WE, Uckun FM.
    Leuk Lymphoma; 1995 Jun 15; 18(1-2):93-102. PubMed ID: 8580835
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. In vivo toxicity and pharmacokinetic features of B43 (anti-CD19)-genistein immunoconjugate in nonhuman primates.
    Messinger Y, Yanishevski Y, Ek O, Zeren T, Waurzyniak B, Gunther R, Chelstrom L, Chandan-Langlie M, Schneider E, Myers DE, Evans W, Uckun FM.
    Clin Cancer Res; 1998 Jan 15; 4(1):165-70. PubMed ID: 9516966
    [Abstract] [Full Text] [Related]

  • 29. In vitro and in vivo cytotoxicity of an anti-osteosarcoma immunotoxin containing pokeweed antiviral protein.
    Anderson PM, Meyers DE, Hasz DE, Covalcuic K, Saltzman D, Khanna C, Uckun FM.
    Cancer Res; 1995 Mar 15; 55(6):1321-7. PubMed ID: 7882330
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models.
    Rosenblum MG, Shawver LK, Marks JW, Brink J, Cheung L, Langton-Webster B.
    Clin Cancer Res; 1999 Apr 15; 5(4):865-74. PubMed ID: 10213223
    [Abstract] [Full Text] [Related]

  • 32. Biotherapy for xenografted human central nervous system leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin.
    Gunther R, Chelstrom LM, Tuel-Ahlgren L, Simon J, Myers DE, Uckun FM.
    Blood; 1995 May 01; 85(9):2537-45. PubMed ID: 7537120
    [Abstract] [Full Text] [Related]

  • 33. An Epstein-Barr virus-infected lymphoblastoid cell line (D430B) that grows in SCID-mice with the morphologic features of a CD30+ anaplastic large cell lymphoma, and is sensitive to anti-CD30 immunotoxins.
    Tazzari PL, de Totero D, Bolognesi A, Testoni N, Pileri S, Roncella S, Reato G, Stein H, Gobbi M, Stirpe F.
    Haematologica; 1999 Nov 01; 84(11):988-95. PubMed ID: 10553158
    [Abstract] [Full Text] [Related]

  • 34. Development of a severe combined immunodeficiency (SCID) mouse model consisting of highly disseminated human B-cell leukemia/lymphoma, cure of the tumors by systemic administration of immunotoxin, and development/application of a clonotype-specific polymerase chain reaction-based assay.
    Yoshida M, Rybak RJ, Choi Y, Greenberg SJ, Barcos M, Kawata A, Matsuno F, Tsai H, Seon BK.
    Cancer Res; 1997 Feb 15; 57(4):678-85. PubMed ID: 9044845
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Effects of the intermolecular toxin-monoclonal antibody linkage on the in vivo stability, immunogenicity and anti-leukemic activity of B43 (anti-CD19) pokeweed antiviral protein immunotoxin.
    Uckun FM, Myers DE, Irvin JD, Kuebelbeck VM, Finnegan D, Chelstrom LM, Houston LL.
    Leuk Lymphoma; 1993 Apr 15; 9(6):459-76. PubMed ID: 7687916
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.